It would be nice to know what they’re thinking as far as ‘commercial opportunity’ goes. Possible partnership for this pillar? With the admission of recent approaches in this space in the 4C hopefully something decent is brewing.
- Forums
- ASX - By Stock
- NOX
- Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
NOX
noxopharm limited
Add to My Watchlist
7.94%
!
6.8¢

Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
6.8¢ |
Change
0.005(7.94%) |
Mkt cap ! $19.87M |
Open | High | Low | Value | Volume |
6.5¢ | 6.9¢ | 6.5¢ | $48.42K | 724.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 6.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.8¢ | 2284 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 0.067 |
1 | 59378 | 0.066 |
1 | 16393 | 0.061 |
1 | 20000 | 0.059 |
1 | 15000 | 0.058 |
Price($) | Vol. | No. |
---|---|---|
0.068 | 2284 | 1 |
0.069 | 90409 | 1 |
0.070 | 261666 | 1 |
0.072 | 43942 | 1 |
0.079 | 50000 | 1 |
Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |